Skip to main content

Table 4 The results of analysis of selected proteins concentrations

From: Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study

Table 4 Control group Stage I/II Stage III Stage IV Stage V p
N=24 N=20 N=20 N=20 N=20
Fetuin A [ng/ml] 102,9±61,1 110,6±74,7 120,1±82,2 102,1±77,4 125,2±63,3 NS
MMP-2 [ng/ml] 103,0±55,7 161,6±105,7 213,0±187,8 270,9±144,5** 228,5±117,6* P=0,002
MMP-9 [ng/ml] 18,4±5,6 16,9±6,5 17,4±5,9 18,0±6,5 18,0±7,6 NS
TIMP-1 [ng/ml] 23,6±2,9 19,9±2,5** 22,1±2,7 21,4±2,5 21,1±1,9* P=0,002
TIMP-2 [ng/ml] 21,0±2,8 21,8±2,2 22,9±1,4* 21,5±2,0 22,0±1,7 NS
MMP-2/TIMP-2 4,7±2,9 7,4±4,6 9,2±7,9 11,9±6,9** 10,5±5,8* P=0,002
MMP-9/TIMP-1 0,93±0,43 0,80±36 0,77±0,26 0,81±0,39 0,83±0,39 NS
Osteocalcin [ng/ml] 6,2±4,0 7,8±4,5 7,0±3,8 5,0±4,4 3,9±4,1 NS
Osteopontin [ng/ml] 38,0±22,5 11,3±5,1 29,7±33,6 29,8±29,9 28,7±19,7 NS
Osteoprotegerin
[pmol/l]
6,0±5,3 4,5±5,6 6,3±5,4 6,4±5,1 8,7±6,1 NS
MGP [ng/ml] 103,7±30,4 105,8±44,4 103,5±29,5 100,7±41,9 88,7±55,0 NS
  1. *p<0.05; **p<0.01 vs control